Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $217,647 - $276,089
5,284 Added 38.78%
18,908 $956,000
Q2 2023

Aug 11, 2023

BUY
$36.89 - $56.88 $74,665 - $115,125
2,024 Added 17.45%
13,624 $636,000
Q1 2023

May 12, 2023

SELL
$37.27 - $50.24 $137,079 - $184,782
-3,678 Reduced 24.07%
11,600 $443,000
Q4 2022

Feb 10, 2023

SELL
$33.44 - $54.8 $22,505 - $36,880
-673 Reduced 4.22%
15,278 $837,000
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $161,902 - $543,131
15,951 New
15,951 $543,000
Q4 2020

Feb 08, 2021

SELL
$25.12 - $29.89 $325,781 - $387,643
-12,969 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$30.79 - $39.92 $399,315 - $517,722
12,969 New
12,969 $399,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.31B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.